News|Radiation Therapy| October 29, 2018

Company showcases latest developments for treatment planning and oncology information systems

RaySearch Demonstrates New Machine Learning Applications at ASTRO

2018年10月29日-RaySearch exhibited its latest advances in oncology software at the 2018 American Society for Radiation Oncology (ASTRO) annual meeting, Oct. 21-24 in San Antonio, Texas, backed bymachine learningand user-friendly tools to enable optimal use of clinical resources. The company showed its latest development in machine learning technology and automation in both its RayStationtreatment planning system (TPS)and RayCareoncology information system (OIS)

With its in-house machine learning department, RaySearch is currently developing machine learning and deep learning prototypes for areas such as treatment plan generation, organ segmentation and target volume estimation. RaySearch is also developing techniques for efficient large-scale data extraction and analysis. The first clinical applications of machine learning are automated treatment planning and automated organ segmentation and will be included in the next RayStation release in December.

The RayCare next-generation OIS is now directly connected to the treatment delivery system at the Provision Cares Proton Therapy facility in Nashville. RayCare is used to manage theradiation therapytreatment sessions. The Nashville center treated their first patient on Oct. 8 and utilizes the RayCare OIS together with the RayStation TPS to plan and manage its proton treatments.

RayCare 2B was released early October and was displayed at the show. This version introduces new features and usability improvements throughout the system, including a feature to support a full treatment delivery and management workflow and task-based offline image review. Other care administration features include support for financial information, such as insurance information and authorization management, and support for managing external contacts, referring clinicians and other external entities.

RaySearch also offered joint product demonstrations with other ASTRO 2018 exhibitors, including:

  • IBA and RaySearch presented their online adaptive proton therapy workflow, where daily optimized plans are created for the individual patient based on cone beam computed tomography (CBCT) images to preserve the original treatment intent. Both companies offered demonstrations including RayCare, RayStation, the AdaPT Insight imaging platform and the AdaPT Deliver treatment delivery. The solution can automatically suggest to the care team an adapted treatment plan that considers the most up-to-date patient anatomy. This workflow offers more accurate treatment plans as well as faster plan adaptation to the benefit of patients;
  • In the Accuray booth, presentations of RayStation and RayCare for the TomoTherapy platform were available. RayStation 8A, released earlier this summer, includes full support for the TomoTherapy and Radixact Systems. All TomoTherapy and Radixact users can now get access to advanced RayStation features, including multi-criteria optimization (MCO), adaptive planning and Plan Explorer; and
  • Mevion Medical Systems showed the latest proton therapy news with the Mevion S250i system with Hyperscan Pencil Beam Scanning demonstrations, using RayStation.

For more information:www.raysearchlabs.com

Related Content

Research has potential to address significant unmet need, identify biomarkers that determine response to treatment
News|Lung Imaging

August 10, 2022 — Mount Sinai is leading a team of lung cancer researchers that has been awarded a three-year, $500,000 ...

TimeAugust 10, 2022
arrow
The U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV infusion for the treatment of patients with unresectable (unable to be removed) or metastatic (spread to other parts of the body) HER2-low breast cancer.
News|2022世界杯篮球预选赛赛程

August 8, 2022 — The U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV ...

TimeAugust 08, 2022
arrow
Dr. Milena Cavic, Institute for Oncology and Radiology of Serbia
News|Lung Imaging

August 8, 2022 — Representatives from the Diagnostics Working Group of the IASLC Early Detection and Screening Committee ...

TimeAugust 08, 2022
arrow
David Gerber, MD
News|Lung Imaging

August 8, 2022 — A clinical trial is only as powerful as its participants. For years, researchers have struggled to fill ...

TimeAugust 08, 2022
arrow
Under this collaboration, IBA will equip the proton therapy system and the proton gantry treatment room at the Fred Hutchinson Cancer Center with ConformalFLASH research functionality, which will enable preclinical research on FLASH therapy.
News|Proton Therapy

August 5, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, Fred ...

TimeAugust 05, 2022
arrow
The oncology information systems market is projected to be worth $2.59 Bn by 2022 and is expected to grow to $5.4 Bn by 2032, at a CAGR of 7.8% from 2022 to 2032.
Feature|Oncology Information Management Systems (OIMS)

August 2, 2022 — The oncology information systems market is projected to be worth $2.59 Bn by 2022 and is expected to ...

TimeAugust 02, 2022
arrow
Portable digital radiography brought to remote locations in Nepal
Feature|Radiology Business| By Melinda Taschetta-Millane

Here is what you and your colleagues found to be most interesting in the field of medical imaging during the month of ...

TimeAugust 01, 2022
arrow
Siemens Healthineers has announced the Food and Drug Administration (FDA) clearance of the ARTIS icono ceiling, a ceiling-mounted angiography system designed for a wide range of routine and advanced procedures in interventional radiology (IR) and cardiology
News|RSNA

July 29, 2022 — The Radiological Society of North America (RSNA), in collaboration with the American Society of ...

TimeJuly 29, 2022
arrow
House-passed Appropriations Bills Include Key Measures to Improve Nuclear Medicine Patient Safety
News|Nuclear Imaging

July 27, 2022 — Patients for Safer Nuclear Medicine, a coalition of 29 patient advocacy organizations representing ...

TimeJuly 27, 2022
arrow
Viz.ai, a leading AI-powered disease detection and intelligent care coordination platform, announced it is partnering with Hyperfine, Inc., creator of the first FDA-cleared point-of-care magnetic resonance imaging (MRI) device, Swoop.
News|Magnetic Resonance Imaging (MRI)

July 27, 2022 — Viz.ai, a leading AI-powered disease detection and intelligent care coordination platform, announced it ...

TimeJuly 27, 2022
arrow
Subscribe Now